Ideas to Action:

Independent research for global prosperity

Global Health Policy

CGD experts discuss such issues as health financing, drug resistance, clinical trials, vaccine development, HIV/AIDS, and health-related foreign assistance.

X

Global Health Policy

Feed

 

A Wake-Up Call on Contraceptive Rates in Africa

Between 1970 and 2010, most emerging countries achieved impressive gains in contraceptive coverage. As a result, their fertility has declined, their population growth rate has slowed down, and many of these countries have been able to capture the economic benefits of the demographic dividend, which occurs when the labor force becomes relatively larger in the total population thanks to lower fertility levels. In addition, the fertility decline improves the dependency ratios and reduces the burden of youth on working adults.

Advancing Solutions in the Sahel

The Sahel region, which stretches from West to East Africa and encompasses parts of about 10 different countries from Senegal to Eritrea, is currently home to 100 million people and is poised to reach 600 million people by the end of the century.  This rapid population growth – indeed, the most rapid on Earth – only exacerbates other challenges in the region including environmental stress, severe poverty and hunger, and intensifying security issues (as exemplified by the

A $400,000 Drug and Why It Matters for Global Health

This year, Revista Epoca reported that a man named Rafael Favaro sued the government of Brazil to obtain public subsidy for lifetime treatment of a rare form of anemia (PNH). His treatment—Soliris—costs Brazilian taxpayers approximately $440,000 per year and is among the most expensive medicines in the world. Most US insurers do not cover the medicine, only Quebec funds the medicine in Canada, and Scotland does not provide any subsidy.

A Global Health Mystery: What’s Behind the US Government Position on AMFm?

As the Global Fund’s November board meeting approaches – where the future of the Affordable Medicines Facility for Malaria (AMFm) hangs in the balance – there is much anxiety that AMFm will be terminated in 2013. The reason for such anxiety is clear: no donors have pledged funding commitments for after December 2012. But there’s another elephant in the room: the US government’s apparent lack of support, particularly its legislated “opt-in” stance on AMFm: “the Global Fund should not support activities involving the ‘Affordable Medicines Facility-malaria’ or similar entities pending compelling evidence of success from pilot programs as evaluated by the Coordinator of United States Government Activities to Combat Malaria Globally.” (Conversely, an opt-out stance would be to support AMFm unless no compelling evidence is presented.) This very specific and strict provision makes the AMFm’s continued survival all but impossible without an explicit endorsement by US Global Malaria Coordinator (currently Rear Admiral Tim Ziemer) who leads the US President’s Malaria Initiative (PMI) housed in the US Agency for International Development (USAID).

Wanted: Global Health Diplomat

The Global Health Initiative was launched by the Obama Administration in 2009 as a new way for the United States to do business in global health. Three years later – suffering from a lack of mandate – the GHI was dissolved and in its place a new new way to do business in global health was announced: the Office of Global Health Diplomacy, led by an Ambassador responsible for “champion[ing] the priorities and policies of the GHI in the diplomatic arena.” The announcement sparked frustration in the global health community, and I questioned if it may be short-sighted to put so much control of US global health leadership into the hands of the State Department.

One Year Later: What Happened to Noncommunicable Diseases?

One year ago, the United Nations held a high-level meeting on non-communicable disease (NCD) prevention and control that culminated in a General Assembly Resolution 66/2 to adopt a 13-page “political declaration” to “address the prevention and control of non-communicable diseases worldwide.” The event presented a united front against NCDs and its flashiness garnered lots of media attention. But one year later, where has the attention and commitment to NCDs gone?

Should UNITAID Rethink Its Raison d’Être?

UNITAID: maybe you’ve heard of it, or maybe not. Launched in 2006, UNITAID has lived in the shadow of its older and bigger global-health siblings (the Global Fund, GAVI, and PEPFAR, to name a few). Perhaps due to its relative obscurity and late entry to a crowded global-health field, UNITAID has proactively worked to differentiate itself through a focus on commodities, market shaping, novel funding sources, and innovation. To wit, UNITAID’s stated mission is “to contribute to scale up access to treatment for HIV/AIDS, malaria and tuberculosis for the people in developing countries by leveraging price reductions of quality drugs and diagnostics, which currently are unaffordable for most developing countries, and to accelerate the pace at which they are made available.”

What’s New in the Child Survival Call to Action?

The newly released new child mortality data by UNICEF has findings that are encouraging yet still worrisome: the world has made progress in reducing child deaths globally; yet each day some 19,000 children die every day largely from preventable causes. USAID highlighted this new publication to remind the world of its “Child Survival Call to Action: Ending Preventable Child Deaths,” co-hosted by USAID, India, Ethiopia, and others on June 14 and 15. Before we completely forget what happened in mid-June, we revisit the event and its desired goals by taking a closer look at the event’s “Roadmap”. Bottom line: The Child Survival Call to Action does not bring much new money or knowledge, but it brings some laudable political attention and a promising emphasis on delivery and accountability. But without more systematic attention from countries and donors, the new child survival agenda risks being another same-old global-health flavor-of-the-month, potentially crowded out by competing priorities in global health.

The Aid Fungibility Debate and Medical Journal Peer Review

The Lancet just published a letter I wrote questioning an influential study in its pages that concluded that most or all foreign aid for health goes into non-health uses. The letter follows up on concerns I expressed in this space in April 2010. Why the 2.5-year lag? Only this past January did the Seattle-based Institute for Health Metrics and Evaluation (IHME) share the data set and computer code that it used to generate the published findings. And only with those in hand could I check my concerns and describe them to others with credibility. (I'm grateful to the kind people at IHME who gave me the data and code, but don't want to let the institution per se off the hook.)

Confusingly, in May the Public Library of Science published another critique of the same article. I questioned that reanalysis, and it was eventually retracted.

Here, I sketch my argument, comment on the reply from Chunling Lu and Christopher Murray, then call out the Lancet for a certain lack of transparency, as well as for sometimes bringing more reputation than rigor to policy-relevant social science research.

Ethiopia’s AIDS Spending Cliff

There’s an AIDS spending cliff in Ethiopia and the government is already in free fall. Next year, Ethiopia will experience a 79% reduction in US HIV financing from PEPFAR. The announcement of these cuts came with an explanation that PEPFAR was “free(ing) up resources by reducing programs in lower HIV prevalence countries” (see blog). Further, Global Fund monies have gone almost completely undisbursed in 2012. These cuts in spending might be warranted due to epidemiological trends and improved efficiency, or might cripple progress as health programs dependent on external donors are cut back. The truth is, with the current poor status of basic information on beneficiaries and costs, it’s difficult to judge whether these cuts are good or bad.

Pages

Tags

Experts